The Defense Health Agency awarded a $213,501 Project Grant to the University Health Network (UHN) under the Military Medical Research and Development program (CFDA 12.420) for the period October 1, 2025 through September 30, 2027. The project, titled "Identification of Molecular Biomarkers for Invasive Glioblastoma Cell States and Tumor Microenvironment Modulation," will be conducted at UHN's facility in Ottawa, Ontario, Canada. This research initiative aims to advance understanding of glioblastoma, a highly aggressive brain cancer affecting military personnel and the general population, by identifying and characterizing molecular biomarkers associated with invasive cancer cell states and investigating approaches to modulate the tumor microenvironment.
As a specialized biomedical research organization with extensive experience in cancer research and clinical studies, UHN will deliver investigative research services including molecular analysis, biomarker identification, and characterization of tumor microenvironmental factors. The research outcomes are expected to contribute to the Defense Health Agency's broader portfolio of medical research supporting Service Member health and advancing innovative cancer treatment strategies. This award aligns with the Military Medical Research and Development program's mission to transform health care through innovative biomedical research addressing conditions affecting the military population.